MTARC1 and metabolic dysfunction-associated steatohepatitis: In the univariate model, we detected a trend for protection against NASH conferred by the MTARC1 polymorphism (p = 0.08), whereas the PNPLA3 variant, hyperlipidemia, and diabetes were all associated with a significantly increased risk of NASH.